PL BioScience develops and produces human platelet lysates for cell culture applications in basic research, cellular therapeutics, and clinical applications.

PL BioScience

We at PL BioScience are experts in cell culture supplements derived from human Platelets. Our mission is to enhance the advances in cellular research and therapy with one forward-looking Technology: ELAREM™.

The ELAREM™ Platform unites tailored cell culture supplements based on Human Platelet Lysate. The human origin combined with a rich growth factor content not only supports cell growth, but also enables various applications: The products cover all needs of cell expansion in academic research, pre-clinical research and cellular therapy. This ensures seamless transitions in regenerative medicine – from lab to patients in need.

Our story goes back to 2015 and the idea to deliver animal component-free cell culture supplements. Today, we have changed the possibilities of cell expansion: Researchers switch from Fetal Bovine Serum to our animal suffering-free products. Stem Cell Therapy benefits the regeneration potential of our platelet-derived products. And we keep moving forward.

Let's create the future of cell expansion together and join us on our mission.

TechVision Fund

PL BioScience GmbH

🚀 Celebrating a Major Milestone – Series A Funding Closed! 🚀

We are excited to share that PL BioScience has successfully closed our Series A financing round, securing an impressive €7.8 million! This significant milestone wouldn’t have been possible without the trust and support of our renowned investors.

A big thank you to the investors who believe in our vision:
AVANT BIO
LePure Biotech
b.value AG
better ventures
Brightlands Venture Partners
TVF | TechVision Fonds

Derived from upcycled donated blood, Human Platelet Lysate (HPL) offers a more ethical, sustainable and animal-free alternative to traditional cell culture media supplements. With this funding, we will be able to expand our production capabilities and solidify our position as a world-class provider of HPL, accelerating the innovations are developing within our product portfolio, and ensuring stable supply to researchers worldwide. 🧪🌎

Of course, none of this would be possible without the dedication of the PL BioScience team. Everyone’s passion and hard work continues to drive us forward. Together, we are helping to shape a xeno-free cell culture future!

Lastly, from all of us in Aachen to all our customers and partners around the world, thank you for your continued support and trust in us. As we enter this new chapter of our company journey, we are excited to reach new heights with everyone! 🌟

Read more in the press release: https://lnkd.in/eWXEje_K

#celltherapy #regenerativemedicine #humanplateletlysate #HPL #PLBS #SeriesA #Investment #Biotechnology #xenofree #aachen #funding

🗓️ Mark your calendars for our webinar on 1st October 2024, 11:00 AM CEST. 

We will dive into a case study: "How Human Platelet Lysate advances 3D MSC Culture"

Dominik Egger, University Professor ”Biofabrication for Drug Testing” at Leibniz Universität Hannover, will present insightful data and methods to generate functional and scalable 3D cell culture models based on HPL.

🧫 An appointment for anyone working in 3D cell culture. 

🔗 Register at: https://lnkd.in/ezZaHHNg

#webinar #cellculture #3dcellculture #biotech #humanplateletlysate

Our colleague Franziska Uber shared her experiences and gained exciting insights at yesterday's ASEAN Business Breakfast in Düsseldorf.

Expanding into any new market can be challenging, but some may be more than others. Countries like Japan have unique cultural quirks to understand and language barriers to overcome, causing some businesses to hesitate to explore the market.

We spoke to the startups from our most recent Japan Market Discovery cohort to hear what they had to say about their recent experience in Japan with us.

If you're interested in experiencing Japan for yourself, find out more and apply for the next cohort here https://lnkd.in/gSGQjdvy

Application deadline: 30 August 2024

PL BioScience GmbH | POROUS | Sciospec Scientific Instruments GmbH | uVida DYNOSTICS | xemX | Jungsoo Park | Julia Eschenbrenner | Jonas Massmann | Sebastian Wegner | Benjamin Said | Lars Banko | Sven Maihöfer

🎆 Happy 4th of July! 🎆

PL BioScience wishes all our American scientific partners and customers a joyful Independence Day! Today, we celebrate the spirit of freedom, innovation, and progress that drives us forward. Thank you for your continued trust and collaboration. 🇺🇸✨

#4thofJuly #IndependenceDay #PLBioScience #PLBS #HPL #humanplateletlysate #ScientificInnovation #Celebration

🔜 One more week until ISSCR 2024 in Hamburg!

From 10-12 July, you will find us at the yearly gathering of stem cell scientists across geographies and disciplines. 🚀

📍Visit us at BOOTH 803 to discover our ELAREM Human Platelet Lysates.

Join Philipp Schmidt and Anna Kolkmann together with 4,000 scientists and let’s dive into the advances in stem cell research and regenerative medicine.

#ISSCR2024 #stemcells #regenerativemedicine #CGT #cellculture #celltherapy #humanplateletlysate

Meet our experts at #ISBTBarcelona. Until 26 June, our colleagues Philipp Schmidt and Sonja Zadel join the transfusion medicine community. Contact them via the conference app or LinkedIn to connect.

#lifesciences #cellculture #celltherapy #transfusionmedicine

🌟Our ELAREM™ HPL family is growing🌟

👉 Get to know the❗GMP version❗of our proven Human Platelet Lysate (HPL) ELAREM™ Perform-FD PLUS.

Your cell culture application is subject to regulatory requirements? The xeno-free cell culture supplement is designed to facilitate the clinical translation of your research.

🧪 Ready-to-use & anticoagulant-free HPL
🧪 For usage in GMP compliant cell culture procedures
🧪 EU origin raw material to fulfil traceability requirements
🧪 Manufacturing under ISO 9001:2015 certified QM system

🔗 Find out more and request your sample: https://lnkd.in/eqbavGAU

#cellculture #celltherapy #bioprocessing #elarem #humanplateletlysate #GMP #launch #teamwork

🌟 Exciting News! 🌟 We’re thrilled to be attending the ISCT, International Society for Cell & Gene Therapy 2024 Conference in Vancouver! 🇨🇦 This is our first time at this prestigious international event, and we can’t wait to connect with fellow experts innovating within the field of cell therapy. 🧬

📍 Booth #240 is where the magic happens! Come visit us to learn about how our xeno-free, research and GMP grade ELAREM™ Human Platelet Lysate (HPL) have been helping scientists around the world advance their research goals. Our team, including Nicholas Gouw and Jungsoo Park, will be there to share insights, answer questions, and discuss the future of HPL in regenerative medicine, from MSCs, to iPSCs, to EV/Exosomes and beyond. 🚀

See you at #ISCT2024! 🙌

#PLBioScience #PLBS #HPL #humanplateletlysate #stemcell #ipsc #exosome #extracellularvesicles #evs #MSCs #mesenchymal #xenofree #ISCT2024 #vancouver #celltherapy #advancedtherapies #conference #exosome

We look back at an inspiring week in Japan. Among five other companies, we joined the Japan Market Discovery Program this month. A great opportunity to set the stage for potential partnerships and innovation across borders.🤝 🌟

news impact assignment basic	general
public peers	general	Aug 22, 2024 3:44 PM	b1b42174
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	dc5cf040
crunchbase profile	general
li profile	general	Aug 22, 2024 3:44 PM	d14a4373
translate crunchbase fundingrounds	general
peers	general	Aug 22, 2024 3:44 PM	328f03ef
news basic	general	Aug 22, 2024 3:44 PM	9c2eb7b5
bundesanzeiger	filings
financials download nd	financials
private financials	financials

PL-B

COM:PL-BIOSCIENCE

PL BioScience